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OBJECTIVES This study sought to evaluate the use of covered Cheatham-platinum (CP) stents in the
treatment of aortic coarctation (CoA).
BACKGROUND Aortic aneurysms and stent fractures have been encountered after surgical and transcatheter
treatment for CoA. Covered stents have previously been used in the treatment of abdominal
and thoracic aneurysms in adults. We implanted covered CP stents as a rescue treatment in
patients with CoA aneurysms or previous stent-related complications and in patients at risk
of developing complications because of complex CoA anatomy or advanced age.
METHODS Thirty-three covered CP stents were implanted in 30 patients; 16 patients had had previous
procedures. The remaining patients had complex or near-atretic CoA.
RESULTS The mean patient age and weight were 28 (17.5) years (range 8 to 65 years), and 62 (13)
kg (range 28 to 86 kg), respectively. The systolic gradient across the CoA decreased from a
mean (SD) of 36  20 mm Hg before to a mean of 4  4 mm Hg after the procedure
(p  0.0001), and the diameter of the CoA increased from 6.4  3.8 mm to 17.1  3.1 mm
(p 0.0001). The follow-up period was up to 40 months (mean, 11 months). All stents were
patent and in good position on computed tomography or magnetic resonance imaging
performed three to six months later. In 43% of the patients antihypertensive medication was
either decreased or stopped.
CONCLUSIONS Covered CP stents may be used as the therapy of choice in patients with complications after
CoA repairs, whereas they provide a safe alternative to conventional stenting in patients with
severe and complex CoA lesions or advanced age. (J Am Coll Cardiol 2006;47:1457–63)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.061© 2006 by the American College of Cardiology Foundation
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ahirty-three covered Cheatham-platinum (CP) stents were
mplanted in 30 patients in three institutions between
eptember 2001 and February 2005. These represent 29%
f 103 patients who underwent stenting of aortic coarctation
CoA) in these institutions during the same period. The
ean age of the patients was 28 (17.5) years (range 8 to 67
ears), and the mean weight was 62 (13) kg (range 28 to
6 kg). Detailed patient characteristics are given in Table 1.
nly four patients were children below 14 years of age (8-,
2-, 13-, and 13-year-olds, weighing 28, 50, 54, and 83 kg,
espectively).
Covered stents were chosen: 1) as a rescue treatment in
atients with CoA aneurysms (Fig. 1) or previous stent-
elated complications (Fig. 2) and 2) in patients at risk of
omplications because of complex CoA anatomy (Fig. 3) or
dvanced age. Complex CoA anatomy was defined as near-
ortic arch interruption or severe arch tortuosity. The latter
oA anatomy was considered high risk for the development
f aneurysms because of the shear forces applied by the stent
nto the intima of the tortuous arch and the high likelihood
f cystic medial necrosis in adult patients with CoA.
dvanced age was defined as age 65 years.
From the *Department of Congenital Heart Disease, Guy’s and St. Thomas’s
ospital, London, United Kingdom; †Department of Congenital Heart Disease,
erman Heart Institute, Berlin, Germany; and the ‡Department of Pediatric
ardiology, Children’s Memorial Hospital, Warsaw, Poland.p
Manuscript received June 12, 2005; revised manuscript received November 10,
005, accepted November 15, 2005.Sixteen of 30 patients had had previous procedures,
onsisting of balloon dilation in 8, stent implantation in 5,
nd surgery in 3. Of these, aneurysms or stent-related
omplications had developed in 12 (such as fractures of
tents, aneurysms, in-stent thrombus) (Fig. 4). Seven pa-
ients had severe, near-atretic native CoA; 7 patients had
nfavorable arch anatomy for conventional stenting (i.e.,
rch tortuosity), 1 of whom had had balloon dilation
reviously; 2 patients had a coexisting patent ductus arteri-
sus; and in 2 patients a covered stent was inserted because
f the severity of the CoA and the advanced age of the
atient (65- and 67-year-olds) (Table 2).
Of the patients in whom covered stents were implanted
o deal with previous aneurysms, five had undergone trans-
atheter interventions and three had undergone surgery.
he mean time for the detection of aneurysm after trans-
atheter intervention was 4.8 months (range 0 to 12
onths) and the mean time from detection to covered stent
mplantation was 16.8 months (range 0 to 48 months). In
he surgical group, covered stents were implanted to deal
ith postoperative aneurysms 17, 30, and 35 years after
epair.
A successful outcome was defined as a peak systolic
ressure gradient after stent implantation of 20 mm Hg.
spirin was used in all patients for 6 weeks to 6 months
fter implantation of a covered CP stent, except for those
atients already on warfarin, in whom aspirin was admin-
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Covered CP Stents for Aortic Coarctation April 4, 2006:1457–63stered the day before the procedure and warfarin was
ecommenced immediately after the procedure.
et-up. All procedures were performed under radiographic
uidance in the cardiac catheterization laboratory, except for
ne, which was performed in the magnetic resonance
maging cardiac catheterization suite, aided by fluoroscopy.
tatistical analysis. Differences in the peak systolic pres-
ure gradient and CoA diameter were assessed by paired t
est analysis. Statistical significance was defined as p 0.05.
aterials. The covered CP stents are currently only avail-
ble outside of the U.S. Covered CP stents are made of a
ramework of platinum iridium wire welded in a zig pattern.
he design consists of formed segments of wire that are
aser-welded together. To facilitate this welded area, the
elbow” sections of the stents are pressed and welded
ogether using laser energy. The welding process takes
aterial from each of the segments being welded together
o make the connection area, but makes each wire slightly
eaker at the welded area because of the removal of
aterial. The addition of a gold soldering to each weld spot
lls any voids caused by the welding and transfers the
tresses to a larger area of the stent (Figs. 5A and 5B). The
old also serves to encapsulate the welded area, once again
dding to the total strength of the weld. The stent is then
tted with a covering of expanded polytetrafluoroethylene
o achieve a solid tubular structure that retains fluid (Figs.
C and 5D). The polytetrafluoroethylene covering is ini-
ially approximately 7 mm in diameter and will stretch over
he range of diameters of expansion (usually from 12 to 24
m diameter), and will always be taut over the stent when
xpanded. When the covering is mounted, it is folded over
he crimped stent and expands uniformly when the balloon
s inflated.
echnique of stent implantation. Informed consent was
btained from all patients or the parents of the children.
he procedure was performed under general anesthesia in
7 patients, sedation with midazolam and propofol in 12
atients, and only local anesthetic in 1 patient who refused
edation. Femoral arterial access was gained percutaneously
n all but 3 patients, in whom surgical arteriotomy was
Abbreviations and Acronyms
CoA  aortic coarctation
CP  Cheatham-platinum
able 1. Patient Characteristics (n  30)
ean age (yrs) 28.3  17.5 (range 8–67)
ean weight (kg) 62  13 (range 28–86)
atients 14 yrs (n) 4
atients 14 to 18 yrs (n) 6
atients 18 yrs (n) 20
ypertension 21 (70%)
solated native aortic coarctation 14 (47%)
revious interventions 16 (53%)wneurysms 8 (27%)erformed. When the CoA lesion was near-atretic, addi-
ional brachial arterial access was obtained for aortic arch
ngiograms and for crossing the CoA with a wire. In one
atient, access was obtained via the femoral vein and the
rocedure was performed in an antegrade fashion through a
entricular septal defect.
After measurement of the initial gradients and angiogra-
hy, the diameters of the transverse arch, CoA, and de-
cending aorta above the diaphragm were measured using
atheter magnification or the calibration markers on the
atheters.
Cheatham-platinum stents covered with expanded poly-
etrafluoroethylene were used in all patients (NuMED Inc.,
opkinton, New York). The length of the chosen stent was
ased on the distance between the left subclavian artery (or
he left common carotid artery if the subclavian artery had
een used at previous surgery) to about 15 mm beyond the
ite of the CoA. The maximum balloon diameter was
hosen based on either the transverse or the distal arch
iameter, whichever was greater, and on occasions 1 to 2
m greater.
A long sheath (usually Mullins, Cook, Bloomington,
ndiana) placed over a 0.035-inch stiff exchange length
uidewire was used in all patients for stent delivery. The
ire was positioned in the ascending aorta in the majority of
ases. The sheath size ranged between 10- and 16-F, and
as chosen to be 2- to 3-F larger than that required for the
ntroduction of the balloon catheters.
The stent was crimped onto a BIB balloon (NuMED
nc.), which is currently available only outside of the U.S.
his balloon allows for readjustment of position after
nflation of the inner balloon. Rapid right ventricular pacing
igure 1. Covered stent implantation for long-segment aortic coarctation
ith aneurysm.as used during stent deployment in eight cases.
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April 4, 2006:1457–63 Covered CP Stents for Aortic CoarctationHemostasis was achieved with the aid of Perclose devices
n 21 of 30 cases (The Closer, Perclose Inc., Menlo Park,
alifornia, and Perclose AT, Abbott Vascular Devices,
edwood City, California). In three patients the arteriot-
my was repaired surgically, whereas in six patients hemo-
tasis was achieved by manual compression. Heparin at a
ose of 50 to 100 IU/kg was given to maintain the activated
lotting time 200 to 220 s during the procedure. Heparin
nfusion or subcutaneous low-molecular-weight heparin was
dministered for a total of 24 h. Antibiotics were given at
he beginning of the procedure and continued for 24 h.
spirin was administered to all patients the evening before
he procedure at a dose of 3 to 5 mg/kg and continued for
weeks to 6 months.
ESULTS
nitial results. A total of 33 covered CP stents were
mplanted successfully in 30 patients. Two patients had two
overed stents inserted on the day of the procedure, one
ecause of a residual gradient of 26 mm Hg after insertion
f the first covered stent and the second because of fracture
igure 2. (A) Fractured stent before covered stent implantation. (B) Same
atient as in panel A after covered stent implantation.f the welds of the covered stent used initially.
F
pMedian fluoroscopy time was 13 min. The systolic gradient
etween ascending and descending aorta decreased from a
ean (SD) of 36 20 mm Hg to a mean of 4 4 mm Hg
p 0.0001), and the diameter of the CoA site increased from
.4  3.8 mm to 17.1  3.1 mm (p  0.0001). When a
overed stent was used to deal with a previous aneurysm, the
atter was completely excluded in all patients.
mmediate complications. Stent fracture was observed at
he soldering joints in two patients. One patient underwent
nsertion of a second stent with reinforced soldering joints,
hereas in the second patient no further stent insertion was
equired. Both of these stents were inserted in the early
hase of our experience, before the newer CP stents with
ortified welding joints became available.
One patient experienced a small subrenal aortic dissection
hat resolved six months later according to a diagnosticigure 3. (A) Atretic aortic coarctation (CoA). (B) Same patient as in
anel A after covered stent implantation.
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Covered CP Stents for Aortic Coarctation April 4, 2006:1457–63ngiogram, and a second patient had a small aneurysm of
he right superficial femoral artery. Two patients experi-
nced hematomas (one secondary to a neck line and the
ther at the site of femoral arterial cannulation). There have
een no late complications.
ubsequent procedures. Four patients underwent further
alloon dilation six months after the initial procedure.
hese were patients with nearly atretic lesions and extended
istal arch hypoplasia, in whom, for safety reasons, we opted
o insert a covered stent as a two-stage procedure with a
uboptimal dilation initially and a full dilation later. The
radient across the CoA site decreased from 5 to 30 mm Hg
fter initial stent implantation to 0 to 10 mm Hg after the
nal stent dilation. One patient with New York Heart
ssociation functional class III and a residual gradient of
5 mm Hg arising from a kink of the arch proximal to the
tent underwent insertion of a second stent to cover the
ink with good results and reduction of the residual
radient to 5 mm Hg.
Figure 4. Breakdown of previous procedures with complicati
able 2. Indications for Insertion of Covered CP Stents
No Previous
Interventions
(n  14)
Previous
Interventions
(n  16)
ear-atretic CoA 7
nfavorable CoA anatomy for
conventional stenting
(tortuous aortic arch and isthmus)
6 1
DA 1 1
neurysms 8
tent-related complications 4
atient age and CoA severity 2p
oA  aortic coarctation; CP  Cheatham-platinum; PDA  patent ductus
rteriosus.ollow-up. The patients have been followed up for a
eriod of up to 40 months (mean 11 months, median 12
onths). Symptomatic patients have reported improvement
f their exercise tolerance, and some patients have noticed
ignificant improvement of their lower limb temperature
nd perfusion.
A spiral computed tomography or magnetic resonance
maging was performed 3 to 6 months after the procedure
nd confirmed good position of the stent, continued patency
f the stent lumen and the head and neck vessels, and no
esidual CoA or aneurysm formation. No late stent fractures
ave been noted in our series to date.
Twenty-one of 30 patients were on antihypertensive
edication before the procedure. In 9 of 21 (43%) patients,
he medication was altered after stent implantation. In
articular, in six patients the total number or dose of antihy-
ertensive medications was reduced, whereas in three patients
he medication was discontinued altogether. The systolic blood
ressure overall decreased from a mean (SD) of 146.6 23.2
m Hg before stent implantation to a mean of 134.2  12.0
m Hg on follow-up (p  0.004).
ISCUSSION
he treatment of CoA has been the focus of many studies
n the past few decades. Surgical repair, first performed by
rafoord and Nylin in 1944 (1), was initially the only
vailable option, but in some cases it was complicated by
estenosis, aneurysm formation (2,3), late hypertension, and
remature death, particularly when the repair was per-
ormed after the first year of life (4,5). To deal with
oA  aortic coarctation; PDA  patent ductus arteriosus.ostoperative complications such as restenosis after surgical
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April 4, 2006:1457–63 Covered CP Stents for Aortic Coarctationepair with subsequent hypertension, balloon dilation of
e-CoA was introduced in 1982 (6–8). It has been a widely
sed technique since then, although not without its prob-
igure 5. (A) Stent weld before and after the gold soldering process. (B)
nd weld encapsulated in gold. (C) Bare welds of the covered
heatham-platinum (CP) stent. (D) Expanded and unexpanded cov-
red CP stent.ems: intimal and medial vessel wall tears, aneurysm forma- tion, residual CoA, and re-CoA have been well described,
hereas the severity of the underlying disease increases the
rocedural morbidity and mortality (4,9,10). Similar com-
lications have been encountered at follow-up of patients
ith native CoA treated with balloon dilation (11–14). The
ncidence of early and late aneurysms after balloon angio-
lasty has been reported to be between 5% and 11.5%
4,7,12–16). Furthermore, increasing age has been found to
e a risk factor for a suboptimal outcome. This has been
ttributed to the presence of fibrotic changes in the aorta
econdary to longstanding obstruction, which may deem the
esion less amenable to ballooning (4,16). Cystic medial
ecrosis observed after percutaneous balloon angioplasty of
oA has also been suggested to be an additional potential
actor contributing to adverse consequences, such as re-CoA
nd aneurysms (17,18).
In the mid-1980s, endovascular stents were used in the
reatment of congenital heart disease (19,20), and a few
ears later balloon-expandable stents were used in the
reatment of CoA in children (21–26). The advantages of
alloon-expandable stents were: 1) provision of support to
he vessel wall and apposition of the torn vessel intima to the
edia, and 2) the ability to perform redilatation to accom-
odate the patient’s somatic growth. Although initially
sed to reduce vessel wall disruption, aneurysm formation
fter stent implantation or aortic dissection after stent
ilatation have also been encountered with this technique in
p to 5% of patients (4,26,27). These complications are
nevitable consequences of the mechanism of dilation of the
oA site and so cannot be completely abolished.
Thoracic atherosclerotic aneurysms and infrarenal aortic
neurysms in adults have been managed with insertion of
tent grafts since the early 1990s (28,29), whereas treatment
f an abdominal aortic pseudoaneurysm with covered
tents in a pediatric patient was first reported in 2000 in
n adolescent girl with neurofibromatosis and abdominal
oA (30).
In 1999, the first covered stent was used to treat coexis-
ent CoA and aneurysm of the aorta in a young man (31).
ince then, very little has emerged in the literature on the
se of covered stents in the treatment of CoA, and the
xisting studies were performed on a small number of
atients (32–37). Several different covered stents have been
sed in the previously mentioned studies: 1) the AneuRx
Medtronic, Watford, England) self-expanding stent cov-
red with a stretchable polytetrafluoroethylene membrane
31); 2) the graft Jomed stents (Jomed, Rangendingen,
ermany) (32); 3) the self-expanding stent grafts (Braile
tent, Braile Biomedica, Sao José do Rio Preto, Brazil) (37);
nd 4) the balloon-expandable Cheatham-platinum stents
overed with expanded polytetrafluoroethylene (Figs. 5C
nd 5D). The latter stents are a more recent introduction
33,34,36,37), and are currently not available in the U.S.
The use of covered CP stents in patients with CoA can
revent or deal with the complications of aneurysm forma-
ion and stent fractures encountered with previously used
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Covered CP Stents for Aortic Coarctation April 4, 2006:1457–63echniques by “sealing” the stenotic dilated area, the aneu-
ysm, or the stent fracture. They provide increased safety in
xtreme forms of CoA or tortuous lesions, and can also be
uccessfully used even in the case of fracture of a covered
tent or a stent graft.
Their use is limited to patients that are (nearly) fully
rown, because currently they can only be redilated up to 25
m, and at diameters of up to 22 mm they can shorten by
ne-eighth of their initial length.
One of the main initial concerns with the use of covered
tents was occlusion of a significant aortic side branch. It is
bviously important to avoid covering the main arteries such
s the innominate or the left common carotid arteries, but
he left subclavian artery can be covered if necessary. The
xperience from vascular radiologists implanting stent grafts
n the thoracic aorta has suggested that stent-graft-induced
cclusion of the ostial left subclavian artery is tolerated well
ithout chronic functional deficit in the absence of stenotic
ertebral and/or carotid arteries and with a documented
ntact vertebrobasilar system (38). Furthermore, occlusion
f a spinal artery, which would result in the most severe
omplication, is unlikely after implantation of a covered
tent in the thoracic aorta, because the spinal artery origi-
ates below the level of the ninth thoracic vertebra in over
0% of the patients (39,40).
Since 2001 we have implanted 33 covered CP stents in 30
atients with complicated lesions after surgical or transcath-
ter repair and in patients at risk of developing complica-
ions because of the complex CoA anatomy (aortic arch and
sthmus tortuosity or near interruption) or advanced age.
ecause covered stents can only be dilated up to a certain
iameter, our patient population was fully grown patients in
7% of cases (26 of 30 patients), whereas 3 of our 4 pediatric
atients were of adult size and weight at the time of the
rocedure.
In all cases, insertion of a covered stent dealt successfully
ith the aneurysmal areas and previous stent fractures with
ood hemodynamic and angiographic results at the end of
he procedure. All aneurysms were completely excluded, and
o aortic side branches were covered during covered stent
mplantation. When used to treat severe native CoA, no
omplications were noted at follow-up, up to 40 months
ater. In two cases, covered CP stents were used to simul-
aneously treat the CoA as well as a patent arterial duct,
hich was covered fully. This indication has been reported
reviously (36,37,41).
Two stent fractures at the soldering joints occurred in the
arly phase of our experience with the initial stent type.
ince May 2002 the covered CP stents have been produced
ith reinforced golden soldering joints (Figs. 5A and 5B).
e believe that stent fracture is unlikely with the reinforced
tent when it is implanted in the target areas, and thus far
e are not aware of any fractures when implanted in theortic position.ONCLUSIONS
ur study is a follow-up evaluation of our previous prelim-
nary experience on the use of covered CP stents for aortic
oA, with inclusion of a much larger number of patients.
ur early and intermediate-term results on the use of
overed CP stents, as a rescue treatment in patients with
oA aneurysms or stent complications and in patients at
isk of developing complications because of complex CoA
natomy, seem encouraging, with potential advantages over
epeat surgery or further conventional stent insertion. Fur-
her studies and late follow-up of these patients are re-
uired.
cknowledgments
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